Budget Impact of the Introduction of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir, the First Integrase Inhibitor-Based Single Tablet Antiretroviral Regimen for HIV Treatment, to Third Party Payers in the United States
Abstract
Authors
A. Brogan S.E. Talbird J.R. Thompson Y.A. Kim J. Olson J. Peterson D. Piontkowsky G. Pietrandoni